Premium intraocular lenses drive Q3 top-line for ophthalmic companies
This article was originally published in Clinica
Advanced Medical Optics (AMO) continued to reap the rewards of its $1.3bn acquisition of refractive surgical company VISX (completed in May this year), with the latter contributing $47.7m to total third-quarter ophthalmic surgical revenues. Sales of laser vision correction (LVC) systems during this period were particularly robust, soaring 71% to $11.1m, compared with VISX's reported system sales in the third quarter last year, and revenues from LVC licensing fees rose 15% to $31.2m.
You may also be interested in...
Draft policy moots crowdfunding for high-cost rare diseases alongside financial support for those "amenable to one-time treatment" but falls way short of some patient groups' expectations.
India’s Hilleman Laboratories says it’s aiming to develop an affordable vaccine that will target pregnant women in low- and middle-income countries to prevent Group B Streptococcus, a potentially fatal infection passed to babies during childbirth.
Chi-Med’s surufatinib has come up trumps in a second trial in neuroendocrine tumors, after the monitoring committee recommended an early halt following achievement of its PFS target in the pancreatic setting.